Journal
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
Volume 32, Issue 14, Pages 2302-2309Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14767058.2018.1432039
Keywords
Newborn; phenobarbital; asphyxia; pharmacokinetics; pharmacodynamics; hypothermia
Categories
Funding
- General University Hospital Project [MH CZ-DRO VFN 64165/2012]
- Intensive Care of the Erasmus MC-Sophia Children's Hospital
- Fund for Scientific Research, Flanders [1800214N]
- Agency for Innovation by Science and Technology in Flanders (IWT) through the SAFEPEDRUG project [IWT/SBO 130033]
Ask authors/readers for more resources
Aim: Phenobarbital (PB) pharmacokinetics (PK) in asphyxiated newborns show large variability, not only explained by hypothermia (HT). We evaluated potential relevant covariates of PK of PB in newborns treated with or without HT for hypoxic-ischemic encephalopathy (HIE). Methods: Clearance (CL), distribution volume (Vd) and elimination half-life (t(1/2)) were calculated using one-compartment analysis. Covariates were clinical characteristics (weight, gestational age, hepatic, renal, and circulatory status), comedication and HIE severity [time to reach normal aEEG pattern (T(norm)aEEG), dichotomous, within 24 h] and asphyxia severity [severe aspyhxia = pH <= 7.1 + Apgar score <= 5 (5 min), dichotomous]. Student's t-test, two-way ANOVA, correlation and Pearson's chi-square test were used. Results: Forty newborns were included [14 non-HT; 26 HT with T(norm)aEEG <24 h in 14/26 (group(1-HT)) and T(norm)aEEG >= 24 h in 12/26 (group(2-HT))]. Severe asphyxia was present in 26/40 [5/14 non-HT, 11/14 and 10/12 in both HT groups]. PB-CL, Vd and t(1/2) were similar between the non-HT and HT group. However, within the HT group, PB-CL was significantly different between group(1-HT) and group(2-HT) (p = .043). ANOVA showed that HT (p = .034) and severity of asphyxia (p = .038) reduced PB-CL (-50%). Conclusion: The interaction of severity of asphyxia and HT is associated with a clinical relevant reduced PB-CL, suggesting the potential relevance of disease characteristics beyond HT itself.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available